GlassScriptPhysician profile
Kenneth M Reed
NPI 1295775732
$208,313.08
in general payments reported to CMS, 2019-2025
29 companies · $482 in 2025
The $482 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $75K · 2021: $46K · 2022: $46K · 2023: $29K · 2024: $979 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,800.00 |
| Food and Beverage | $1,460.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $192,766.65 | 2020-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $6,979.15 | 2019-2024 | Siliq, Duobrii |
| Abbvie INC. | $2,144.70 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $1,479.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $960.13 | 2019-2025 | |
| Janssen Biotech, INC. | $817.23 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $528.84 | 2019-2024 | Taltz, Ebglyss |
| Pfizer INC. | $447.20 | 2019-2025 | |
| Leo Pharma INC. | $420.76 | 2019-2025 | Adbry |
| Genzyme Corporation | $326.79 | 2019-2025 | |
| Celgene Corporation | $277.71 | 2019 | |
| Ucb, INC. | $199.82 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $149.86 | 2024-2025 | Sotyktu |
| Amgen INC. | $135.45 | 2019-2021 | |
| Biofrontera INC. | $127.06 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $84.32 | 2019-2020 | |
| Genentech USA, INC. | $75.27 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $61.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $53.39 | 2019-2024 | Libtayo |
| Sun Pharmaceutical Industries INC. | $51.72 | 2019-2021 | |
| Merz North America, INC. | $41.56 | 2019-2021 | |
| Incyte Corporation | $40.18 | 2021-2025 | Opzelura |
| Strata Skin Sciences, INC. | $30.52 | 2019-2021 | |
| Allergan, INC. | $30.50 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $29.27 | 2019 | |
| Misonix INC | $21.95 | 2021 | |
| Galderma Laboratories, L.P. | $17.29 | 2019 | |
| Aclaris Therapeutics, INC. | $15.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.